| Hazard Information | Back Directory | [Uses]
Ciraparantag TFA is a thrombin and factor Xa inhibitor. Ciraparantag TFA is a broad-spectrum reversal agent for anticoagulants, including low-molecular-weight heparin, unfractionated heparin, and certain direct oral anticoagulants. It is reported to antagonize the effects of all coagulants except VKAs and agratroban[1][2][3][4]. | [References]
[1] Das A, et al. Novel antidotes for target specific oral anticoagulants. Exp Hematol Oncol. 2015 Sep 15;4:25. DOI:10.1186/s40164-015-0020-3
[2] Gomez-Outes A, et al. Specific antidotes in development for reversal of novel anticoagulants: a review. Recent Pat Cardiovasc Drug Discov. 2014;9(1):2-10. DOI:10.2174/1574890109666141205132531
[3] Hu TY, et al. Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab. Vasc Health Risk Manag. 2016 Feb 17;12:35-44. DOI:10.2147/VHRM.S89130
[4] Honickel M, et al. The Reversal of Direct Oral Anticoagulants in Animal Models. Shock. 2017 Aug;48(2):144-158. DOI:10.1097/SHK.0000000000000848 |
|
|